A landmark investigation reveals Oregon’s licensed psilocybin service centers are exceeding safety and compliance standards, but economic barriers limit broader access.

Congress’s PATH Caucus outlines a federal–state roadmap to integrate psychedelic-assisted therapy into U.S. care with clinical safeguards, data tracking and provider standards.

Federal health officials and clinical experts met in Silver Spring to establish safety, credentialing, and access standards for psychedelic medicines.

Lawmakers are advancing therapy-only psychedelics models. Without home cultivation, advocates warn access stays gated and the Drug War’s logic lives on.

A new nonprofit, After The Story, will fund legal psychedelic-assisted care and integration for reporters and media workers carrying trauma from the job.

New York's amended Medical Psilocybin Act outlines clinical access rules, offering a therapeutic model for the East Coast and DMV region.

New federal signals and Big Pharma interest set the stage as Horizons comes back to New York. Here’s what DMV residents should watch, and how policy, access, and culture may evolve next.

FDA guidance, Phase 3 results and VA-led training signal psychedelic therapies edging closer to clinics. Here’s what practitioners—and DMV patients—should know now.

An in-depth look at ICPR 2026 research, clinical trial findings, regulatory hurdles, and implications for medical cannabis and patient care.